Prescribing of adrenaline auto-injectors
- Gurnaaz Kaur Kahlon1
© Kahlon; licensee BioMed Central Ltd. 2015
Published: 30 March 2015
Anaphylaxis is a severe and life threatening hypersensitivity reaction.
Individuals at risk can be offered an adrenaline auto-injector to use in the event of an attack. The dose required is dependent on the brand of adrenaline auto injector and the weight of the patient as outlined in The British National Formulary (BNF):
Anapen Over 30kg 0.3mg
Over 60kg 0.5mg
Epipen 15-30kg 0.15mg (Unlicensed for less than 15kg)
Over 30kg 0.3mg
Jext 15-30kg 0.15mg (Unlicensed for less than 15kg)
Over 30kg 0.3mg
For the adrenaline to be effective it is imperative that the correct dose is administered.
To determine if patients at a general practice in East London are being prescribed the correct dose of adrenaline auto injector as outlined in the BNF.
Design: Using the computerised medical records system patients using an adrenaline auto-injector over a 21 month period were identified. Following this, the latest weight of the patient was identified and the dose of adrenaline prescribed.
25 patients were identified who had been prescribed an adrenaline auto-injector. 11 of these had been prescribed an Epipen Jr (0.15mg) and 14 the Epipen (0.3mg).
2 patients (both children) had been prescribed the wrong dose for their weight. Of the remaining 9 patients on an Epipen Jr (all children), 4 had not had a weight recorded in the last year thus may potentially be on the wrong dose.
Adrenaline auto-injector doses are weight dependent and without weight monitoring the wrong dose can be prescribed. This is particularly important in children thus prescribers need to be aware of the need to monitor their weight in anticipation of a need to increase the dose. Measures should be put in place at general practices to promote awareness; recommendations include local teaching and prompts on the electronic medical records systems to remind prescribers to review the dose.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.